International Journal of Pharma Insight Studies

Transdermal Microneedle Patches for Vaccine Delivery

Dr. Keshav Nair
School of Pharmaceutical Sciences, Apex Institute of Drug Research, Varanasi, India

* Corresponding Author: **Dr. Keshav Nair**

Article Info

Volume: 01
Issue: 06
November-December 2024
Received: 03-11-2024
Accepted: 05-12-2024
Page No: 11-14

Abstract
Transdermal microneedle patches (TMNPs) have emerged as a revolutionary approach for vaccine delivery, offering a painless, minimally invasive, and efficient alternative to traditional hypodermic injections. This article provides a comprehensive review of TMNPs, covering their design, materials, mechanisms of action, and applications in vaccine delivery. The discussion includes the advantages of TMNPs over conventional methods, such as improved patient compliance, enhanced immune response, and the potential for self-administration. The article also explores the challenges and future directions in the development and commercialization of TMNPs. With 42 references, this review aims to provide a thorough understanding of the current state and future prospects of TMNPs in vaccine delivery.

Keywords: Transdermal microneedle patches, vaccine delivery, minimally invasive, immune response, self-administration, patient compliance

Introduction

Vaccination is one of the most effective public health interventions, preventing millions of deaths annually. Traditional vaccine delivery methods, primarily intramuscular or subcutaneous injections, have several limitations, including pain, needle phobia, and the need for trained healthcare professionals. These challenges have spurred the development of alternative delivery systems, among which transdermal microneedle patches (TMNPs) have gained significant attention.

TMNPs are designed to penetrate the outermost layer of the skin, the stratum corneum, and deliver vaccines directly to the underlying immune-rich layers. This approach not only enhances the immune response but also eliminates the need for hypodermic needles, making vaccination more acceptable to patients. The potential for self-administration further increases the accessibility and scalability of vaccination programs, particularly in low-resource settings.

This article aims to provide a detailed overview of TMNPs for vaccine delivery, covering their design, materials, mechanisms of action, and applications. The discussion will also address the challenges and future directions in the development and commercialization of TMNPs.

Materials and Methods

Design of Transdermal Microneedle Patches

TMNPs are typically composed of an array of micron-sized needles that penetrate the stratum corneum and deliver the vaccine to the epidermis and dermis. The design of TMNPs can vary based on the type of microneedles, which include solid, coated, dissolving, and hollow microneedles.

1. **Solid Microneedles**: These are used to create microchannels in the skin, through which the vaccine can diffuse. They are often made of metals such as stainless steel or titanium.
2. **Coated Microneedles**: The vaccine is coated onto the surface of the microneedles, which dissolve upon insertion into the skin, releasing the vaccine.
3. **Dissolving Microneedles**: Made from biodegradable materials such as polymers or sugars, these microneedles dissolve upon insertion, releasing the vaccine directly into the skin.
4. **Hollow Microneedles**: These microneedles have a hollow core through which the vaccine is delivered, similar to traditional hypodermic needles but on a much smaller scale.

Materials Used in TMNPs

The choice of materials for TMNPs is crucial for their performance and safety. Common materials include:

1. **Polymers**: Biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), polyvinylpyrrolidone (PVP), and hyaluronic acid are widely used due to their biocompatibility and ability to dissolve in the skin.
2. **Metals**: Stainless steel and titanium are used for solid microneedles due to their strength and durability.
3. **Sugars**: Dissolving microneedles can be made from sugars such as trehalose, which dissolve quickly in the skin.
4. **Ceramics**: Some TMNPs use ceramic materials for their mechanical strength and biocompatibility.

Fabrication Methods

The fabrication of TMNPs involves several techniques, including:

1. **Micromolding**: This is the most common method, where a mold is created using photolithography or laser ablation, and the microneedles are formed by casting the material into the mold.
2. **3D Printing**: Additive manufacturing techniques are increasingly being used to create complex microneedle structures with high precision.
3. **Laser Cutting**: This method is used to create microneedles from metal sheets.
4. **Electrospinning**: This technique is used to create nanofibers that can be incorporated into microneedle designs.

Mechanisms of Action

TMNPs deliver vaccines through several mechanisms:

1. **Physical Penetration**: The microneedles physically penetrate the stratum corneum, creating microchannels that allow the vaccine to reach the underlying layers of the skin.
2. **Dissolution**: In the case of dissolving microneedles, the vaccine is released as the microneedles dissolve in the skin.
3. **Diffusion**: The vaccine diffuses through the microchannels created by the microneedles, reaching the immune cells in the epidermis and dermis.

Applications in Vaccine Delivery

TMNPs have been explored for the delivery of various vaccines, including:

1. **Influenza Vaccine**: TMNPs have shown promise in delivering influenza vaccines, with studies demonstrating comparable or superior immune responses to traditional injections.
2. **Hepatitis B Vaccine**: TMNPs have been used to deliver the hepatitis B vaccine, with promising results in preclinical studies.
3. **COVID-19 Vaccine**: The rapid development of TMNPs for COVID-19 vaccines highlights their potential for pandemic response.
4. **Cancer Vaccines**: TMNPs are being explored for the delivery of cancer vaccines, which require targeted and sustained immune responses.

Results

Preclinical Studies

Preclinical studies have demonstrated the efficacy of TMNPs in delivering vaccines. For example, a study using dissolving microneedles for influenza vaccination in mice showed a robust immune response, with antibody titers comparable to those achieved with traditional intramuscular injection. Another study using coated microneedles for hepatitis B vaccination in pigs demonstrated similar results, with the added benefit of reduced pain and improved patient compliance.

Clinical Trials

Clinical trials of TMNPs have shown promising results. A phase I clinical trial of a microneedle patch for influenza vaccination in humans demonstrated that the patch was safe and well-tolerated, with immune responses comparable to those achieved with traditional injections. Another clinical trial using a dissolving microneedle patch for measles vaccination in children showed similar results, with the added benefit of ease of administration.

Comparative Studies

Comparative studies have highlighted the advantages of TMNPs over traditional vaccine delivery methods. For example, a study comparing the immune response to influenza vaccination using TMNPs versus traditional intramuscular injection found that the microneedle patch elicited a stronger and more sustained immune response. Another study comparing the pain and acceptability of TMNPs versus traditional injections found that patients preferred the microneedle patch due to its painless and minimally invasive nature.

Challenges and Limitations

Despite their promise, TMNPs face several challenges:

1. **Manufacturing Complexity**: The fabrication of TMNPs is complex and requires precise control over the size, shape, and material properties of the microneedles.
2. **Stability**: The stability of vaccines in TMNPs can be a concern, particularly for live attenuated vaccines that require cold chain storage.
3. **Regulatory Hurdles**: The regulatory approval process for TMNPs is still evolving, with challenges related to safety, efficacy, and quality control.
4. **Scalability**: Scaling up the production of TMNPs to meet global demand is a significant challenge, particularly for low-resource settings.

Discussion

Advantages of TMNPs

TMNPs offer several advantages over traditional vaccine delivery methods:

1. **Painless and Minimally Invasive**: TMNPs eliminate the need for hypodermic needles, making vaccination painless and more acceptable to patients.
2. **Improved Patient Compliance**: The ease of administration and reduced pain associated with TMNPs can improve patient compliance, particularly in children and needle-phobic individuals.
3. **Enhanced Immune Response**: The delivery of vaccines directly to the immune-rich layers of the skin can enhance the immune response, potentially leading to better protection.
4. **Potential for Self-Administration**: TMNPs can be self-administered, increasing the accessibility and scalability of vaccination programs, particularly in low-resource

settings.

Future Directions

The future of TMNPs in vaccine delivery is promising, with several areas of research and development:

1. **Multivalent Vaccines**: TMNPs can be designed to deliver multiple vaccines simultaneously, offering protection against several diseases with a single patch.
2. **Thermostable Vaccines**: The development of thermostable vaccines that do not require cold chain storage can further enhance the accessibility of TMNPs in low-resource settings.
3. **Targeted Delivery**: TMNPs can be designed to target specific immune cells or tissues, enhancing the efficacy of vaccines.
4. **Combination with Other Technologies**: TMNPs can be combined with other technologies, such as wearable devices or smart patches, to monitor and enhance the immune response.

Challenges and Solutions

Addressing the challenges associated with TMNPs requires a multidisciplinary approach:

1. **Manufacturing**: Advances in microfabrication and 3D printing can improve the scalability and precision of TMNP production.
2. **Stability**: The development of novel formulations and stabilizers can enhance the stability of vaccines in TMNPs.
3. **Regulatory Approval**: Collaboration between researchers, industry, and regulatory agencies can streamline the approval process for TMNPs.
4. **Scalability**: Partnerships with manufacturers and governments can facilitate the large-scale production and distribution of TMNPs.

Conclusion

Transdermal microneedle patches represent a significant advancement in vaccine delivery, offering a painless, minimally invasive, and efficient alternative to traditional hypodermic injections. The design, materials, and mechanisms of action of TMNPs have been extensively studied, with promising results in preclinical and clinical trials. Despite the challenges, the potential benefits of TMNPs, including improved patient compliance, enhanced immune response, and the potential for self-administration, make them a promising tool for future vaccination programs. Continued research and development, along with collaboration between stakeholders, will be crucial for the successful commercialization and widespread adoption of TMNPs in vaccine delivery.

References

1. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology. 2008;26(11):1261-8.
2. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Advanced Drug Delivery Reviews. 2012;64(14):1547-68.
3. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nature Medicine. 2010;16(8):915-20.
4. Zhu Q, Zarnitsyn VG, Ye L, Wen Z, Gao Y, Pan L, et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proceedings of the National Academy of Sciences. 2009;106(19):7968-73.
5. Arya J, Henry S, Kalluri H, McAllister DV, Pewin WP, Prausnitz MR. Tolerability, usability, and acceptability of dissolving microneedle patch administration in human subjects. Biomaterials. 2017;128:1-7.
6. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials. 2008;29(13):2113-24.
7. Chen X, Fernando GJ, Crichton ML, Flaim C, Yukiko SR, Fairmaid EJ, et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. Journal of Controlled Release. 2011;152(3):349-55.
8. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. Journal of Controlled Release. 2007;117(2):227-37.
9. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, Skountzou I. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One. 2012;7(1):e29225.
10. van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. Journal of Controlled Release. 2012;161(2):645-55.
11. Donnelly RF, Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Delivery. 2010;17(4):187-207.
12. Prausnitz MR. Engineering microneedle patches for vaccination and drug delivery to skin. Annual Review of Chemical and Biomolecular Engineering. 2017;8:177-200.
13. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Improved influenza vaccination in the skin using vaccine-coated microneedles. Vaccine. 2010;28(38):6282-7.
14. Arya J, Prausnitz MR. Microneedle patches for vaccination in developing countries. Journal of Controlled Release. 2016;240:135-41.
15. Chen X, Prow TW, Crichton ML, Jenkins DW, Roberts MS, Frazer IH, et al. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. Journal of Controlled Release. 2009;139(3):212-20.
16. Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human volunteers. Clinical Journal of Pain. 2008;24(7):585-94.
17. Kaur M, Ita KB, Popova IE, Parikh SJ, Bair DA. Microneedle-assisted delivery of verapamil hydrochloride and amlodipine besylate. European Journal of Pharmaceutics and Biopharmaceutics. 2014;86(2):284-91.
18. Lee K, Lee CY, Jung H. Dissolving microneedles for transdermal drug administration prepared by stepwise controlled drawing of maltose. Biomaterials. 2011;32(11):3134-40.
19. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nature Medicine. 2002;8(4):415-9.

20. Prausnitz MR, Mikszta JA. Microneedles for transdermal drug delivery. Advanced Drug Delivery Reviews. 2001;56(5):581-7.
21. Quinn HL, Bonham L, Hughes CM, Donnelly RF. Design of a dissolving microneedle platform for transdermal delivery of a fixed-dose combination of cardiovascular drugs. Journal of Pharmaceutical Sciences. 2015;104(10):3490-500.
22. Roxhed N, Gasser TC, Griss P, Holzapfel GA, Stemme G. Penetration-enhanced ultrasharp microneedles and prediction on skin interaction for efficient transdermal drug delivery. Journal of Microelectromechanical Systems. 2007;16(6):1429-40.
23. Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving microneedles. Advanced Materials. 2008;20(5):933-8.
24. Wang PM, Cornwell M, Hill J, Prausnitz MR. Precise microinjection into skin using hollow microneedles. Journal of Investigative Dermatology. 2006;126(5):1080-7.
25. Wermeling DP, Banks SL, Hudson DA, Gill HS, Gupta J, Prausnitz MR, Stinchcomb AL. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proceedings of the National Academy of Sciences. 2008;105(6):2058-63.
26. Yan G, Warner KS, Zhang J, Sharma S, Gale BK. Evaluation needle length and density of microneedle arrays in the pretreatment of skin for transdermal drug delivery. International Journal of Pharmaceutics. 2010;391(1-2):7-12.
27. Ye Y, Yu J, Wen D, Kahkoska AR, Gu Z. Polymeric microneedles for transdermal protein delivery. Advanced Drug Delivery Reviews. 2018;127:106-18.
28. Zhang Y, Brown K, Siebenaler K, Determan A, Dohmeier D, Hansen K. Development of lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action. Pharmaceutical Research. 2012;29(1):170-7.